Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
Status:
Terminated
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop
the growth of cancer cells. It may also stop the patient's immune system from rejecting the
donor's stem cells. The donated stem cells may replace the patient's immune cells and help
destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted
cells from a donor can also make an immune response against the body's normal cells. Giving a
monoclonal antibody, such as alemtuzumab, before transplant and tacrolimus and methotrexate
after transplant may stop this from happening.
PURPOSE: This phase II trial is studying the side effects of donor stem cell transplant and
to see how well it works in treating patients with high-risk hematologic cancer.